What Will Trump Do in Davos, if He Comes: DealBook Briefing
- 6 years ago
What Will Trump Do in Davos, if He Comes: DealBook Briefing
• Populism — though, Mr. Trump aside, anxiety is on the wane (NYT)
• How long the world’s economies can continue to expand (NYT)
• How to respond to cyberwarfare by the likes of North Korea (NYT)
• How to improve women’s standing in the world, with several top women leaders in attendance (NYT)
• Big tech companies’ image woes (FT)
• France’s efforts to woo business leaders, including a pre-Davos summit at Versailles
that will be attended by Jamie Dimon and Sheryl Sandberg (Reuters)
The father of Jared Kushner, who is again working at the family real estate business — this time without a title — told the WaPo in an interview
that the Kushner Companies hasn’t been a target of the Russia investigation so far and hasn’t had problems getting financing.
: Citigroup, Perella Weinberg Partners and the law firm Debevoise & Plimpton
For Validus: JPMorgan Chase and the law firm Skadden, Arps, Slate, Meagher & Flom
In offering to buy the Juno shares that it doesn’t already own for about $9 billion, Celgene is adding a maker of blood disease treatments.
• Populism — though, Mr. Trump aside, anxiety is on the wane (NYT)
• How long the world’s economies can continue to expand (NYT)
• How to respond to cyberwarfare by the likes of North Korea (NYT)
• How to improve women’s standing in the world, with several top women leaders in attendance (NYT)
• Big tech companies’ image woes (FT)
• France’s efforts to woo business leaders, including a pre-Davos summit at Versailles
that will be attended by Jamie Dimon and Sheryl Sandberg (Reuters)
The father of Jared Kushner, who is again working at the family real estate business — this time without a title — told the WaPo in an interview
that the Kushner Companies hasn’t been a target of the Russia investigation so far and hasn’t had problems getting financing.
: Citigroup, Perella Weinberg Partners and the law firm Debevoise & Plimpton
For Validus: JPMorgan Chase and the law firm Skadden, Arps, Slate, Meagher & Flom
In offering to buy the Juno shares that it doesn’t already own for about $9 billion, Celgene is adding a maker of blood disease treatments.